miR-1297 targeted AM, blocked its expression, and sensitized glioma cells to TMZ treatment; this could be mediated by the Bax/Bcl-2, Akt, and extracellular signal-regulated protein kinase (ERK)1/2 signaling pathways [221]. The gene discussed is MAPK3; the disease is central nervous system cancer.